ASA 81 MG TABLET (DELAYED-RELEASE)

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

ACETYLSALICYLIC ACID

Prieinama:

LABORATOIRES TRIANON INC.

ATC kodas:

B01AC06

INN (Tarptautinis Pavadinimas):

ACETYLSALICYLIC ACID

Dozė:

81MG

Vaisto forma:

TABLET (DELAYED-RELEASE)

Sudėtis:

ACETYLSALICYLIC ACID 81MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

120/150/300

Recepto tipas:

OTC

Gydymo sritis:

SALICYLATES

Produkto santrauka:

Active ingredient group (AIG) number: 0101169013; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2015-12-11

Prekės savybės

_ASA 81 MG - Product Monograph _
_ _
_Page 1 of 44 _
PRODUCT MONOGRAPH
ASA 81 MG
Acetylsalicylic
Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
LABORATOIRES TRIANON INC.
660 Boul. Industriel
Blainville,
Quebec
J7C 3V4
www.labriva.com
Date of Preparation:
December 11, 2015
Date of Revision:
September 28, 2022
Control Number: 267165
_ASA 81 MG - Product Monograph _
_ _
_Page 2 of 44 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS
............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
4
ADVERSE
REACTIONS.............................................................................................
6
DRUG INTERACTIONS
.............................................................................................
7
DOSAGE AND ADMINISTRATION
..........................................................................
9
OVERDOSAGE
.........................................................................................................10
ACTION AND CLINICAL
PHARMACOLOGY.........................................................11
STORAGE AND STABILITY
....................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
..........................................12
PART II: SCIENTIFIC INFORMATION
..........................................................................
13
PHARMACEUTICAL INFORMATION
.....................................................................13
CLINICAL TRIALS
...................................................................................................14
DETAILED
PHARMACOLOGY.......................